Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Sep 28, 2022

Sharon L. Rogers Ph.D. is the CEO of AmyriAD Therapeutics and has a deep understanding of the development of drugs to address the impact of Alzheimer's disease. Currently, the most common treatment is Aricept which Sharon developed and brought to market in 1996. Based on recent research, it does not appear that disease modification leads to clinical benefit or reduction in the progression of the disease.

Sharon explains, "We're not doing anything that's going to modify the underlying progression of the disease, at least that we know of. This is a relentless disease, and sooner or later, it will run its course, and the outcome is ultimately fatal. But, we can buy time for people. Whenever you can improve function, you can reduce reliance on skilled nursing care. You can reduce reliance on the caregiver and the burden that it brings to the loved ones of the patients. You can prolong the time to nursing home placement, which is just really horrible for everyone involved, the families and the patients."

"It is a simple tablet that will be administered once a day by mouth with just a little bit of water going with it. And as a matter of fact, this drug is designed to be administered as an adjunct to Aricept. Aricept is the standard of care. And so we want to maintain the Aricept treatment, but when you give AD101 on top of it as an oral drug, it increases the effects that were there before. So you'd have an additive improvement in cognition and global function."

@AmyriAD_Tx #Alzheimersdisease #Alzheimers #AD #BrainHealth #MentalHealth #AlzheimersAwareness #MemoriesAreWorthFightingFor

amyriadtherapeutics.com

Download the transcript here

AmyriAD